Tag Archives: Mead Johnson

Pfizer Ponders A Move

A few months ago, pharma giant Pfizer (PFE) got a boost when Sanford Bernstein analyst Tim Anderson (and a few other street colleagues) mentioned that company management was open to spinning off or selling parts of the business.  This set off a flurry of reports analyzing potential castaways with estimates ending up as high as 4 divisions shed… Read More »